Japan PMDA Registration: What Turkish Exporters Need to Know
The MAH Requirement — Japan's Most Important Regulatory Feature
Japan's medical device regulation (MHLW Ordinance) requires that all medical devices placed on the Japanese market be covered by a Marketing Authorisation Holder (MAH — 製造販売業者). The MAH must be a Japanese entity (company or individual) licensed by Japan's prefectural authority. Foreign companies cannot be MAHs directly.
This means: A Turkish manufacturer cannot independently register its devices in Japan. The Turkish manufacturer must find a Japanese distributor or third-party MAH service provider willing to act as MAH for its products. The MAH bears full regulatory responsibility in Japan — post-market surveillance, adverse event reporting, and product recalls are the MAH's legal obligation.
Consequence: Your Japanese distributor is not just a commercial partner — they are your regulatory proxy. The selection of a Japanese distributor is simultaneously a regulatory decision.
Part 02Japan's Medical Device Classification
| Japanese Class | Risk Level | Pathway | Equivalent |
|---|---|---|---|
| Class I — 一般医療機器 | Lowest | Todoke (notification) — self-declaration by MAH | EU Class I (non-sterile, non-measuring) |
| Class II — 管理医療機器 | Low-Moderate | Nintei (third-party certification) OR Todoke with QMS certification | EU Class IIa/IIb |
| Class III — 高度管理医療機器 (non-implantable) | Moderate-High | Ninsho (PMDA approval) | EU Class IIb |
| Class IV — 高度管理医療機器 (implantable) | Highest | Ninsho (PMDA approval) + clinical data | EU Class III |
Todoke vs Nintei vs Ninsho — Understanding the Pathways
- Todoke (届出) — Self-declaration: Applies to Class I devices and some Class II with a recognised standard. MAH submits notification to PMDA. No PMDA review required. Fastest pathway: 1–3 months.
- Nintei (認証) — Third-party certification: Applies to Class II devices covered by a Designated Standards list. A Japanese Registered Certification Body (RCB) reviews technical documentation and issues a certification. ISO 13485 and CE documentation substantially supports the review. Timeline: 6–12 months.
- Ninsho (承認) — PMDA Approval: Required for Class III and IV devices. Full PMDA technical review — most demanding, longest timeline (18–36 months), highest cost. Equivalent in scope to EU Class IIb/III NB review but with additional Japan-specific clinical evidence requirements.
How CE Documentation Supports PMDA Registration
Japan's MHLW has a CE Mark recognition framework — CE technical documentation provides a foundation for PMDA registration, though it is not a direct acceptance pathway:
- ISO 13485: Directly recognised — Japanese QMS certification requirements align with ISO 13485; CE-certified manufacturers' QMS satisfies the base Japanese QMS requirement
- ISO 14971 risk management: Accepted — PMDA reviews risk management files; CE-format ISO 14971 files are accepted
- Performance testing data: Accepted when conducted to JIS (Japanese Industrial Standards) or internationally recognised standards — most ISO/ASTM/IEC standards are accepted
- Clinical data: PMDA has historically required Japanese clinical data or bridging studies for implantable and life-sustaining devices — this requirement has been progressively relaxed but remains for high-risk Class III/IV devices
- Summary Technical Documentation (STD): Japan uses its own summary documentation format (Summary Technical Documentation, 基本要件 summary) — CE Technical File content must be reformatted to PMDA's STD format
Practical Pathway for Turkish Manufacturers
- Identify Japanese MAH/distributor: Engage a Japanese medical device distributor with MAH license and QMS (GQP — Good Quality Practice) certification in your device category. MAH service companies (specialised third-party MAH providers) are available for manufacturers who do not want distributor dependency.
- Classify your device under Japanese GHTF/JMDA classification: Japanese classification sometimes differs from EU/FDA — verify correct Japanese class with your MAH before preparing documentation
- Prepare STD (Summary Technical Documentation): Reformat CE Technical Documentation into Japan STD format with Japanese translations of key sections
- QMS registration: Japanese manufacturing site QMS (JPAL — Japan Pharmaceutical Affairs Law QMS) registration with prefectural authority — typically managed by MAH
- Submit to PMDA or RCB: Class II Nintei to RCB; Class III/IV Ninsho to PMDA directly
Timeline and Cost Reality
| Device Class | Pathway | Realistic Timeline | Indicative Cost |
|---|---|---|---|
| Class I | Todoke | 1–3 months | USD 5,000–15,000 (MAH fees) |
| Class II | Nintei (RCB) | 6–12 months | USD 30,000–60,000 |
| Class III | Ninsho (PMDA) | 18–30 months | USD 80,000–150,000 |
| Class IV | Ninsho + clinical | 24–36+ months | USD 150,000–400,000+ |
These costs are indicative and include MAH service fees, PMDA/RCB fees, regulatory consulting, and Japanese translation. Clinical bridging studies for Class III/IV are not included and can add substantially to the investment.